MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
about
Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemiaAKT-dependent phosphorylation of Niban regulates nucleophosmin- and MDM2-mediated p53 stability and cell apoptosisTargeting Cancer Metabolism - Revisiting the Warburg EffectsThe Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal CancerOther targeted drugs in melanomaTargeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?The PTEN tumor suppressor gene and its role in lymphoma pathogenesisEmerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorderInhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significanceExploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?Drugs for allosteric sites on receptorsNovel agents in mantle cell lymphomaGrowth factor signaling to mTORC1 by amino acid-laden macropinosomes.AMIGO2, a novel membrane anchor of PDK1, controls cell survival and angiogenesis via Akt activation.A kinome-wide RNAi screen in Drosophila Glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastomaDiscovery of Potent and Selective Covalent Inhibitors of JNKTargeting the RAS oncogene.Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.Therapeutic targeting of cancers with loss of PTEN function.Role of Akt signaling in resistance to DNA-targeted therapyMaximising the potential of AKT inhibitors as anti-cancer treatmentsIn vitro models of cancer stem cells and clinical applicationsDeciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)The phosphoinositide 3-kinase pathway and therapy resistance in cancerThe critical role of Akt in cardiovascular functionLysyl oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesisNetwork-level effects of kinase inhibitors modulate TNF-α-induced apoptosis in the intestinal epitheliumEGFR-TKI resistance in NSCLC patients: mechanisms and strategiesAllosteric interactions between the myristate- and ATP-site of the Abl kinaseA switch from canonical to noncanonical Wnt signaling mediates drug resistance in colon cancer cellsComputational insights into the inhibitory mechanism of human AKT1 by an orally active inhibitor, MK-2206An Atomic Force Microscope Study Revealed Two Mechanisms in the Effect of Anticancer Drugs on Rate-Dependent Young's Modulus of Human Prostate Cancer CellsTargeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C ReleaseHigh-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.Akt3 is responsible for the survival and proliferation of embryonic stem cellsAsymmetric cancer cell division regulated by AKTThe small GTPase Rap1b negatively regulates neutrophil chemotaxis and transcellular diapedesis by inhibiting Akt activation.In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.
P2860
Q24310753-48DB6B16-5333-4557-97A0-FD55C21C2A52Q24314880-B6DB32A2-105C-409D-9BC1-107CA82456B2Q26738876-D1171AC7-DA5C-4A15-A7D4-2C22EED76D84Q26744721-3B846546-6494-48C0-AF02-EFE5F2D9A8FAQ26775594-243C3E2E-4168-4739-A8B5-2D0D39261A1CQ26775940-D8365240-F160-4930-9C8B-8901ECD09886Q26776527-B4274A26-190E-42E9-A229-C44A231770DEQ26859114-44B7795D-A3B9-428F-8A7B-B569A530C86CQ26991637-FC6EF728-9239-41CF-B2D6-DB946E027080Q27001584-3B89A9B2-A2F8-46B5-8A48-29F6D8E59E7DQ27006721-3BD8D047-8017-4267-A0FE-2D0EC5FF4412Q27011763-5FE83446-6896-4183-863F-612BD5D999EDQ27309327-3BBBEAE7-453C-4763-923B-01A33ACC91A3Q27309773-9188BA52-208D-481B-BF32-AA8BE6972500Q27324733-02C15C48-9301-4782-86D7-3C7F1F0190B1Q27676927-B7C62AE2-3F24-42A6-9220-562AEFFF4B3FQ27687198-84BBB6EB-F9BC-4410-8DC7-847F4A0BA305Q27852553-1EED36C3-84D6-4BBF-98BD-ED3C46FAE1B9Q27852764-7629A1BB-5C5B-4BD2-A290-BA2941E24713Q28066950-D8BF87AB-8A40-4EC6-AD68-EAC48C42AD9AQ28072254-9F5A27FC-AC3C-4EF9-A6D6-9C13B3AB6D49Q28076101-9535789D-E900-444C-9AE8-8A55C416E50DQ28079848-1CEC60E0-C3B8-4325-B641-F88755E8B989Q28080599-C634A54C-DCA6-4EC5-B94C-D4F8177679ADQ28082811-D50466A6-3F0E-4CC1-A02B-3226EEBCBC79Q28083829-447360E3-5683-45C4-95E2-384C48651956Q28280138-0259622F-8BD5-44FA-97CE-85BDD70C6FCDQ28390885-29474B71-0DFD-499D-BEED-D7AF92FD1796Q28394310-23AAC0B6-53F3-4AAB-854D-B5A1E51D56BCQ28476718-A7DA2A44-2BF7-430C-843D-0CD83C4624CFQ28477795-27458B3D-3FD6-41B8-9621-5DBB52304301Q28543899-1C4153AA-BC5F-4C7B-80B7-76A4AC76BB50Q28546930-E9E514E9-E8B0-45C1-B067-7A63F0F337CBQ28550300-141D378A-3E1B-4E5E-8B5E-30E17B27D12AQ28550350-9D53B3A4-4F97-4E13-B93A-6984D9A4551CQ30433183-1E013E6D-2F1A-4695-B726-6A040AAC8FE7Q30491624-C899B8CC-9756-4F6B-A77E-07375134D262Q30503288-E5A96040-AE2F-4DE2-96C2-F7DE4D862D79Q30586319-54707A07-35FC-49ED-BCF0-8DDB2ABBF08AQ33601377-3E014037-87D3-4D68-BF95-BFDB994E857B
P2860
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
MK-2206, an allosteric Akt inh ...... ed drugs in vitro and in vivo.
@en
type
label
MK-2206, an allosteric Akt inh ...... ed drugs in vitro and in vivo.
@en
prefLabel
MK-2206, an allosteric Akt inh ...... ed drugs in vitro and in vivo.
@en
P2093
P1476
MK-2206, an allosteric Akt inh ...... ed drugs in vitro and in vivo.
@en
P2093
Bo-Sheng Pan
Harold Hatch
Hidehito Kotani
Hiroshi Hirai
Hiroshi Sootome
Katsuyoshi Miyama
Kyoko Tsujioka
Pradip K Majumder
Shunsuke Taguchi
Yoko Nakatsuru
P304
P356
10.1158/1535-7163.MCT-09-1012
P577
2010-06-22T00:00:00Z